三生制药
3SBIO INC.

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 01530)

VOLUNTARY ANNOUNCEMENT
707 Injection (Anti-VEGF/PD-1 Bispecific Antibody) Granted Breakthrough Therapy Designation by NMPA

This announcement is made by 3SBio Inc. (the "**Company**", together with its subsidiaries, "**3SBio**") on a voluntary basis.

On 17 April, 2025, the anti-VEGF/PD-1 bispecific antibody (R&D code: 707 Injection), independently developed by 3SBio, was granted a Breakthrough Therapy Designation ("**BTD**") by China's National Medical Products Administration ("**NMPA**"). The designated indication is the first-line treatment of PD-L1 positive locally advanced or metastatic non-small cell lung cancer ("**NSCLC**").

707 Injection is a bispecific antibody targeting VEGF/PD-1, independently developed by 3SBio based on its proprietary CLF2 platform. It is currently undergoing multiple clinical studies in China, including a phase III clinical study for the first-line treatment of PD-L1 positive locally advanced or metastatic NSCLC already approved by the Center for Drug Evaluation ("**CDE**") of the NMPA. Additionally, 707 Injection is undergoing several phase II studies in China, including combination therapy with chemotherapy for the first-line treatment of advanced NSCLC, metastatic colorectal cancer, and advanced gynecological tumours. It has also received approval from the U.S. Food and Drug Administration in relation to its Investigational New Drug application.

The CDE will provide policy support for drugs that have been granted BTDs, prioritize resource allocation for communication, enhance guidance, and accelerate drug development. When submitting a New Drug Application, if it is evaluated to meet the relevant conditions, the qualification for priority review and approval may be granted, expediting the market launch process.

There is no assurance that the product will eventually be commercialized successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
3SBio Inc.
Dr. LOU Jing
Chairman

Hong Kong SAR, the PRC
17 April 2025

As at the date of this announcement, the Board comprises Dr. LOU Jing and Ms. SU Dongmei as executive Directors; Ms. ZHANG Jiaoe as non-executive Director; and Mr. PU Tianruo, Ms. YANG, Hoi Ti Heidi, and Mr. NG, Joo Yeow Gerry as independent non-executive Directors.